Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Christopher C Porter

TitleAssoc Professor Adjoint
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PEDS
Phone303/724-4665

    Collapse Biography 
    Collapse awards and honors
    1995Peacock Family Award for Outstanding Performance in Gross Anatomy, Medical College of Georgia
    1998Alpha Omega Alpha Honor Medical Society, Medical College of Georgia
    2003 - 2004Ruth L. Kirschstein National Research Service Award, University of Colorado School of Medicine
    2004W.M. Thorkildson Research Fellowship, University of Colorado School of Medicine
    2005 - 2006Brent Eley/Brian Hicks Research Award, Brent Eley Foundation
    2008 - 2009Paul Calabresi Clinical Scholars Award, University of Colorado Cancer Center
    2011Scholars Award, Hyundai Hope on Wheels Foundation
    2013Acute Lymphoblastic Leukemia Young Investigator Award, CureSearch

    Collapse Overview 
    Collapse overview
    Dr. Porter is a Pediatric Hematologist-Oncologist with extensive training in basic, translational, and clinical sciences. After clinical training in pediatrics and pediatric hematology-oncology, he joined the laboratory of James DeGregori, Ph.D. for training in Biochemistry & Molecular Genetics. After fellowship, he was awarded the Paul Calabresi Clinical/Translational Scholars Award, which provided mentorship and training in Experimental Therapeutics with Lia Gore, M.D. He now runs a lab with the goal of improving the care of patients with leukemia. His lab now consists of 6 others focused on identifying and validating novel strategies for treating leukemia through functional genomic screening with RNA-interference libraries and translational murine models of disease. The clinical implications of these projects are emphasized, with the concrete goal of translating laboratory findings into clinical trials. In addition to directing the lab, he is the Study Chair/PI of an investigator initiated, NCI supported trial (NCT01456988) which translates preclinical data from similar functional genomics studies by "re-purposing" cyclosporine to inhibit WNT/calcineurin/NFAT signaling to sensitize BCR-ABL1+ leukemia cells to tyrosine kinase inhibition.

    Several members of the lab are currently working on further validation of one particular molecule, WEE1 that, when inhibited, sensitizes acute myeloid leukemia cells to cytarbaine. WEE1 is a cell cycle checkpoint protein kinase that is activated to stall cell cycle progression in the context of DNA damage. Using shRNA and a small molecule inhibitor in clinical development, the lab has demonstrated that inhbition of WEE1 is synergistic with cytarabine in inhibiting AML cell proliferation by inhibiting the S-phase checkpoint and inducing apoptosis. These data are being confirmed in mouse models of leukemia including primary patient xenografts. Clinical trials testing the combination of cytarabine and WEE1 inhibition are being planned.


    Collapse Research 
    Collapse research activities and funding
    R21HL094921     (PORTER, CHRISTOPHER C)Apr 15, 2009 - Mar 31, 2012
    NIH/NHLBI
    Testing the safety and efficacy of inhibitory RNA mediated purine analog resistan
    Role: Principal Investigator

    R01CA172385     (PORTER, CHRISTOPHER C)Jul 1, 2013 - Apr 30, 2018
    NIH/NCI
    Validation and Development of WEE1 as a therapeutic target in AML
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ellison MA, Gearheart CM, Porter CC, Ambruso DR. IFN-? alters the expression of diverse immunity related genes in a cell culture model designed to represent maturing neutrophils. PLoS One. 2017; 12(10):e0185956. PMID: 28982143.
      View in: PubMed
    2. Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC. A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. Mol Cancer Ther. 2017 Oct; 16(10):2058-2068. PMID: 28655785.
      View in: PubMed
    3. Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017 Apr; 15(4):382-394. PMID: 28108622.
      View in: PubMed
    4. Porter CC. Germ line mutations associated with leukemias. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):302-308. PMID: 27913495.
      View in: PubMed
    5. Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget. 2016 Mar 29; 7(13):15757-71. PMID: 26909599; PMCID: PMC4941275.
    6. Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter CC. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget. 2015 Sep 29; 6(29):28001-10. PMID: 26334102; PMCID: PMC4695040.
    7. Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015 Nov 05; 126(19):2202-12. PMID: 26324703; PMCID: PMC4635116.
    8. Ellison MA, Thurman G, Gearheart CM, Seewald RH, Porter CC, Ambruso DR. INF-? Enhances Nox2 Activity by Upregulating phox Proteins When Applied to Differentiating PLB-985 Cells but Does Not Induce Nox2 Activity by Itself. PLoS One. 2015; 10(8):e0136766. PMID: 26317224; PMCID: PMC4552644.
    9. Kirkpatrick G, Noetzli L, Di Paola J, Porter CC. ETV6 mutations define a new cancer predisposition syndrome. Oncotarget. 2015 Jul 10; 6(19):16830-1. PMID: 26219557; PMCID: PMC4627276.
    10. Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A, Rajpurkar M, Jones K, Gowan K, Balduini C, Pecci A, Gnan C, De Rocco D, Doubek M, Li L, Lu L, Leung R, Landolt-Marticorena C, Hunger S, Heller P, Gutierrez-Hartmann A, Xiayuan L, Pluthero FG, Rowley JW, Weyrich AS, Kahr WHA, Porter CC, Di Paola J. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015 May; 47(5):535-538. PMID: 25807284; PMCID: PMC4631613.
    11. Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res. 2014 May 01; 74(9):2579-90. PMID: 24590058; PMCID: PMC4008672.
    12. Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013 Dec; 12(12):2675-84. PMID: 24121103; PMCID: PMC3897395.
    13. Choudhary R, Baturin D, Fosmire S, Freed B, Porter CC. Knockdown of HPRT for selection of genetically modified human hematopoietic progenitor cells. PLoS One. 2013; 8(3):e59594. PMID: 23555045; PMCID: PMC3598703.
    14. Gore L, DeGregori J, Porter CC. Targeting developmental pathways in children with cancer: what price success? Lancet Oncol. 2013 Feb; 14(2):e70-8. PMID: 23369685; PMCID: PMC3673778.
    15. Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012 Aug 15; 72(16):4154-64. PMID: 22738915; PMCID: PMC3673784.
    16. Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol. 2012 Jul; 8(7):646-54. PMID: 22660439; PMCID: PMC3430605.
    17. Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, DeGregori J. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia. 2012 Jun; 26(6):1266-76. PMID: 22289989; PMCID: PMC3678731.
    18. Porter CC, Baturin D, Choudhary R, DeGregori J. Relative fitness of hematopoietic progenitors influences leukemia progression. Leukemia. 2011 May; 25(5):891-5. PMID: 21331070; PMCID: PMC3670417.
    19. Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J. Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol. 2010 Mar 02; 8(3):e1000324. PMID: 20208998; PMCID: PMC2830447.
    20. Schlegel J, Redzic JS, Porter CC, Yurchenko V, Bukrinsky M, Labeikovsky W, Armstrong GS, Zhang F, Isern NG, DeGregori J, Hodges R, Eisenmesser EZ. Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. J Mol Biol. 2009 Aug 21; 391(3):518-35. PMID: 19500591; PMCID: PMC2940942.
    21. Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer. 2009 Feb; 52(2):298-300. PMID: 18837430.
      View in: PubMed
    22. Porter CC, Liang X, Gralla J, McGavran L, Albano EA. BCL6 expression correlates with monomorphic histology in children with posttransplantation lymphoproliferative disease. J Pediatr Hematol Oncol. 2008 Sep; 30(9):684-8. PMID: 18776761; PMCID: PMC2652168.
    23. Porter CC, DeGregori J. Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection. Blood. 2008 Dec 01; 112(12):4466-74. PMID: 18587011; PMCID: PMC2597122.
    24. Gheorghe G, Albano EA, Porter CC, McGavran L, Wei Q, Meltesen L, Danielson SM, Liang X. Posttransplant Hodgkin lymphoma preceded by polymorphic posttransplant lymphoproliferative disorder: report of a pediatric case and review of the literature. J Pediatr Hematol Oncol. 2007 Feb; 29(2):112-6. PMID: 17279008.
      View in: PubMed
    25. Bilousova G, Marusyk A, Porter CC, Cardiff RD, DeGregori J. Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol. 2005 Dec; 3(12):e401. PMID: 16277552; PMCID: PMC1283331.
    26. Porter CC, Edwards KM, Zhu Y, Frangoul H. Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004 Jan; 42(1):36-40. PMID: 14752792.
      View in: PubMed
    27. Porter CC, Poehling KA, Hamilton R, Frangoul H, Cooper WO. Influenza immunization practices among pediatric oncologists. J Pediatr Hematol Oncol. 2003 Feb; 25(2):134-8. PMID: 12571465.
      View in: PubMed
    Porter's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)